

Innovations in Tuberculosis Treatment: Navigating Challenges and Enhancing Outcomes

Monday, March 25, 2024 | 2:00 — 3:00 pm ET



COURSE # 588-605-24

DESCRIPTION

Recently, new options for treatment of both drug susceptible and drug resistant *Mycobacterium tuberculosis* infections have been developed. In this webinar subject matter experts will discuss current guidelines, clinical considerations and laboratory tests involved with the use of new regimens including the shorter course rifapentine-moxifloxacin regimen and the bedaquiline, pretomanid, and linezolid (BPaL) regimen.

AUDIENCE

This program is intended for anyone who works in or supervises a public health or clinical laboratory, including clinical and public health laboratory staff, microbiology students, epidemiologists and research scientists. Persons working in public health departments and health care practitioners interested in TB may also benefit from the content of this webinar.

OBJECTIVES

After completing this webinar the participant will be able to:

- Describe the current guidelines for use of the 4-month rifapentine-moxifloxacin and BPaL regimens and discuss the benefits of each.
- Identify and compare the available laboratory tests associated with new TB treatments.

SPEAKERS

Presenters

- **Jessica Gentry**, mycobacteriology supervisor, Laboratory Services, Indiana Department of Health
- **Janice Louie, MD MPH**, medical director, TB Prevention and Control Program, San Francisco Department of Public Health
- **Caitlin Reed, MD MPH**, medical officer team lead, Field Services Branch, NCHHSTP, DTE, CDC

Moderator

Max Salfinger, MD FAAM FIDSA ATSF, professor of public health practice (Ret.), University of South Florida College of Public Health

ENROLL FOR FREE

Enrollment via the link above is required to access the live webinar. If you need assistance with enrollment, please email alc@aphl.org. To participate in this live webinar, log in to the [APHL Learning Center \(ALC\)](#) and follow [these instructions](#). If accessing the [APHL Learning Center \(ALC\)](#) for the first time, [create a free APHL account](#).

Online Access

To participate in this webinar, all you need is a high-speed Internet connection to access [ZOOM](#), the program site. To get started, check out the Top Questions section of the [FAQ](#) page.

Continuing Education

The Association of Public Health Laboratories (APHL) is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program. P.A.C.E.® is accepted by all licensure states except Florida. This learning activity will provide 1.0 contact hours for the participant who successfully completes this training.

Level of Instruction:

INTERMEDIATE: Refresher course; some basic knowledge required; for the experienced staff technologist with some years of experience.

ACCESSIBILITY

In compliance with the Americans with Disabilities Act, individuals seeking special accommodations must email a request to Ashton Blair (Ashton.blair@aphl.org) prior to the live webinar. Closed captions will be available with the webinar recording.

LEARN MORE

For more information about this webinar, please email infectious.diseases@aphl.org.

By registering for this event, you are consenting to have your information shared with APHL event collaborators, such as the Centers for Disease Control and Prevention and Public Health Laboratories. We will not, in any circumstances, share your information with other individuals or organizations without your permission, including corporations or individuals, except when applicable by law. We do not sell, communicate or divulge your information to any mailing lists.

This webinar is supported by Cooperative Agreement number NU600E000104 (CFDA No. 93.322), funded by the Centers for Disease Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention or the Department of Health and Human Services, or APHL and member laboratories. This project was 100% funded with federal funds from a federal program of \$1,634,760.